Skip to main content

HCPCS Level II

HCPCS Level II 1998 code changes

Every HCPCS Level II code whose CMS add date or termination date falls in 1998, grouped by effective date. Each code's own page carries its full record.

48
Added
0
Deleted

For HCPCS Level II, MedCoder records each code's CMS add date and termination date from the alpha-numeric file. A deletion is listed on the first day the code is no longer valid (the day after its CMS termination date). Description revisions between quarterly files are not recorded as changes.

Added effective January 1, 1998 (30)

  • A9502 — Technetium tc-99m tetrofosmin, diagnostic, per study dose
  • A9600 — Strontium sr-89 chloride, therapeutic, per millicurie
  • E0371 — Nonpowered advanced pressure reducing overlay for mattress, standard mattress length and width
  • E0372 — Powered air overlay for mattress, standard mattress length and width
  • E0373 — Nonpowered advanced pressure reducing mattress
  • E0855 — Cervical traction equipment not requiring additional stand or frame
  • G0101 — Cervical or vaginal cancer screening; pelvic and clinical breast examination
  • G0104 — Colorectal cancer screening; flexible sigmoidoscopy
  • G0105 — Colorectal cancer screening; colonoscopy on individual at high risk
  • G0106 — Colorectal cancer screening; alternative to g0104, screening sigmoidoscopy, barium enema
  • G0120 — Colorectal cancer screening; alternative to g0105, screening colonoscopy, barium enema.
  • G0121 — Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk
  • G0122 — Colorectal cancer screening; barium enema
  • G0127 — Trimming of dystrophic nails, any number
  • J0207 — Injection, amifostine, 500 mg
  • J0735 — Injection, clonidine hydrochloride, 1 mg
  • J0740 — Injection, cidofovir, 375 mg
  • J1325 — Injection, epoprostenol, 0.5 mg
  • J1626 — Injection, granisetron hydrochloride, 100 mcg
  • J1742 — Injection, ibutilide fumarate, 1 mg
  • J9201 — Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
  • J9206 — Injection, irinotecan, 20 mg
  • J9600 — Injection, porfimer sodium, 75 mg
  • K0455 — Infusion pump used for uninterrupted parenteral administration of medication, (e.g., epoprostenol or treprostinol)
  • L0999 — Addition to spinal orthosis, not otherwise specified
  • L1843 — Knee orthosis, single upright, thigh and calf, with adjustable flexion and extension joint (unicentric or polycentric), medial-lateral and rotation control, with or without varus/valgus adjustment, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
  • L2035 — Knee ankle foot orthosis, full plastic, static (pediatric size), without free motion ankle, prefabricated, includes fitting and adjustment
  • L5826 — Addition, endoskeletal knee-shin system, single axis, hydraulic swing phase control, with miniature high activity frame
  • L8039 — Breast prosthesis, not otherwise specified
  • L8699 — Prosthetic implant, not otherwise specified

Added effective April 1, 1998 (14)

  • G0123 — Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision
  • G0124 — Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician
  • G0128 — Direct (face-to-face with patient) skilled nursing services of a registered nurse provided in a comprehensive outpatient rehabilitation facility, each 10 minutes beyond the first 5 minutes
  • Q0163 — Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen
  • Q0164 — Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
  • Q0166 — Granisetron hydrochloride, 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen
  • Q0167 — Dronabinol, 2.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
  • Q0169 — Promethazine hydrochloride, 12.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
  • Q0173 — Trimethobenzamide hydrochloride, 250 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
  • Q0174 — Thiethylperazine maleate, 10 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
  • Q0175 — Perphenazine, 4 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
  • Q0177 — Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
  • Q0180 — Dolasetron mesylate, 100 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen
  • Q0181 — Unspecified oral dosage form, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for a iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

Added effective July 1, 1998 (4)

  • G0108 — Diabetes outpatient self-management training services, individual, per 30 minutes
  • G0109 — Diabetes outpatient self-management training services, group session (2 or more), per 30 minutes
  • G0130 — Single energy x-ray absorptiometry (sexa) bone density study, one or more sites; appendicular skeleton (peripheral) (e.g., radius, wrist, heel)
  • K0462 — Temporary replacement for patient owned equipment being repaired, any type

Source: CMS HCPCS Level II alpha-numeric file (add and termination dates).

Source data

Source organization
CMS
Source release
HCPCS Level II October 2026 alpha-numeric file
Source file
october-2026-alpha-numeric-hcpcs-file.zip
File checksum (SHA-256)
c25240c63108756d4ba6c0ea785c517117d83bfed9526c51da8acf123de1feb6
Data read date
Data not available in the current MedCoder release record.
Effective date
CMS effective dates within 1998
Release type
Quarterly (January, April, July, October), with occasional mid-quarter additions
Methodology
Each code's add date and termination date are read from the alpha-numeric file. A deletion is dated the first day the code is no longer valid, the day after its termination date. Description revisions are not recorded as changes.

These changes are based on recorded release data. MedCoder does not generate coding changes with AI.

All releases in the Change Ledger